AU2015279705B2 - Acinetobacter lysins - Google Patents

Acinetobacter lysins Download PDF

Info

Publication number
AU2015279705B2
AU2015279705B2 AU2015279705A AU2015279705A AU2015279705B2 AU 2015279705 B2 AU2015279705 B2 AU 2015279705B2 AU 2015279705 A AU2015279705 A AU 2015279705A AU 2015279705 A AU2015279705 A AU 2015279705A AU 2015279705 B2 AU2015279705 B2 AU 2015279705B2
Authority
AU
Australia
Prior art keywords
seq
leu
gly
lys
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015279705A
Other languages
English (en)
Other versions
AU2015279705A1 (en
Inventor
Vincent Fischetti
Rolf LOOD
Raymond Schuch
Benjamin WINER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of AU2015279705A1 publication Critical patent/AU2015279705A1/en
Application granted granted Critical
Publication of AU2015279705B2 publication Critical patent/AU2015279705B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04—Macromolecular materials
    • A61L29/043—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/15—Laboratory, medical or dentistry appliances, e.g. catheters or sharps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015279705A 2014-06-26 2015-06-26 Acinetobacter lysins Ceased AU2015279705B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017618P 2014-06-26 2014-06-26
US62/017,618 2014-06-26
PCT/US2015/037962 WO2015200783A2 (en) 2014-06-26 2015-06-26 Acinetobacter lysins

Publications (2)

Publication Number Publication Date
AU2015279705A1 AU2015279705A1 (en) 2017-01-19
AU2015279705B2 true AU2015279705B2 (en) 2021-04-01

Family

ID=54938953

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015279705A Ceased AU2015279705B2 (en) 2014-06-26 2015-06-26 Acinetobacter lysins

Country Status (14)

Country Link
US (2) US10590403B2 (enExample)
EP (1) EP3164146B1 (enExample)
JP (1) JP6818349B2 (enExample)
KR (1) KR102441211B1 (enExample)
CN (1) CN106659748B (enExample)
AU (1) AU2015279705B2 (enExample)
BR (1) BR112016030580B1 (enExample)
CA (1) CA2953446A1 (enExample)
ES (1) ES2767294T3 (enExample)
GB (1) GB2543453A (enExample)
IL (1) IL249636A0 (enExample)
NZ (1) NZ728429A (enExample)
RU (1) RU2725809C2 (enExample)
WO (1) WO2015200783A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016030580B1 (pt) * 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF
MX2021012166A (es) * 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
CN111909917B (zh) * 2019-05-10 2022-10-14 中国科学院微生物研究所 一种内溶素Lysmeta1及其编码基因与应用
WO2021180892A1 (en) 2020-03-11 2021-09-16 Telum Therapeutics S.L. New recombinant lysin and its use in the treatment of gram-negative bacterial infections
KR102604590B1 (ko) * 2020-09-28 2023-11-23 경북대학교 산학협력단 아시네토박터 바우마니에 대한 사멸능을 가지는 박테리오파지 및 이를 포함하는 조성물
KR102419028B1 (ko) * 2021-01-06 2022-07-08 주식회사 리신바이오 박테리오파지 유래 신규 재조합 엔도라이신 및 이의 용도
WO2022236088A1 (en) * 2021-05-06 2022-11-10 Bioharmony Therapeutics Inc. Lysin polypeptide compositions and methods of use
KR102776341B1 (ko) * 2023-11-24 2025-03-10 경북대학교 산학협력단 아시네토박터 바우마니에 대한 특이적 결합능을 갖는 재조합 단백질 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562958B1 (en) * 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
KR20130129326A (ko) * 2012-05-18 2013-11-28 연세대학교 산학협력단 카바페넴 제제에 내성을 보이는 아시네토박터 균속을 용균하는 박테리오파아지

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113298A1 (en) * 1997-10-31 2003-06-19 Vincent Fischetti Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses
US6056954A (en) * 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US5997862A (en) * 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US6133010A (en) 1999-07-08 2000-10-17 Biotec Asa Chlamysin B antibacterial protein, a protein gene for and an expression system for same
US20100233146A1 (en) * 2002-09-09 2010-09-16 Reactive Surfaces, Ltd. Coatings and Surface Treatments Having Active Enzymes and Peptides
US7604975B2 (en) * 2002-10-01 2009-10-20 The Rockefeller University Glycosylated LPXTGases and uses thereof
CA2534060C (en) * 2003-07-30 2012-06-12 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US20070077235A1 (en) * 2004-01-16 2007-04-05 Lawrence Loomis Composition and method of treating mastitis
EP2078529B1 (en) 2006-07-10 2014-12-10 PBA3 Biomed GmbH Antimicrobial peptides
US9999635B2 (en) * 2007-01-16 2018-06-19 Realm Therapeutics, Inc. Methods and compositions for treating inflammatory disorders
EP2217614A4 (en) * 2007-11-07 2011-12-07 Dynamic Microbials Ltd ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND APPLICATIONS THEREOF
EP2157100A1 (en) * 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2371840B1 (en) * 2008-11-28 2014-04-16 AnGes MG, Inc. Novel polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes
KR101016918B1 (ko) * 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
PL2445515T3 (pl) * 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
JP5847081B2 (ja) * 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ．ユー． ルーベン アール アンド ディー エンドリシンＯＢＰｇｐＬＹＳ
WO2011084882A2 (en) * 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
RU2614114C2 (ru) * 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
GB201103780D0 (en) * 2011-03-04 2011-04-20 Hansa Medical Ab Treatment for ige-mediated disease
MX383544B (es) * 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
US9872843B2 (en) * 2011-10-08 2018-01-23 Next Science, Llc Antimicrobial compositions and methods employing same
AU2013259512B2 (en) * 2012-05-09 2018-01-25 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
RU2646102C2 (ru) * 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
JP2015530987A (ja) * 2012-08-08 2015-10-29 アヴァシン・ファーマシューティカルズ・インコーポレーテッド 耐性の可能性が低い抗微生物剤標的の阻害
CN102940874B (zh) * 2012-12-12 2013-12-18 中国科学院昆明动物研究所 小分子多肽cw14在制备山羊抗菌药物中的应用
EP2986115A4 (en) * 2013-02-06 2017-03-01 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
BR112016030580B1 (pt) * 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
CN106480070B (zh) * 2015-08-25 2023-10-20 厦门大学 一种用于展示目的多肽的多肽载体及其用途
ES2934714T3 (es) * 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas
CN109152822B (zh) * 2016-05-12 2023-12-05 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法
CN117018170A (zh) * 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
WO2019191633A2 (en) * 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20210198644A1 (en) * 2018-05-23 2021-07-01 The Rockefeller University Recombinant lysins
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562958B1 (en) * 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
KR20130129326A (ko) * 2012-05-18 2013-11-28 연세대학교 산학협력단 카바페넴 제제에 내성을 보이는 아시네토박터 균속을 용균하는 박테리오파아지

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A0A009YLP0_ACIBA, Lysozyme Gene J500_0845 from Acinetobacter sp. 479375, Uniprot Accession No. A0A009YLP0_ACIBA, 11 June 2014 [online]. Retrieved from the internet URL: http://www.uniprot.org/uniprot/A0A009YLP0 whole doc. *
FASTA Accession No. ADX03203; 2012 Sequence shares 90.56% identity with SEQ ID NO: 12 and 92.22% identity with SEQ ID NO: 18 *
FASTA Accession No. AEP05453; 2011Sequence shares 100% identity with SEQ ID NO: 7 and 10 ; 99.2% with SEQ ID NO: 9 and 93.55% with SEQ ID NO: 11 *
FASTA Accession No. AFU37285; 2012Sequence shares 100% identity with SEQ ID NO: 7 and 10 ; 99.2% with SEQ ID NO: 9 and 93.55% with SEQ ID NO: 11 *
FASTA Accession No. AGQ13366; 2013Sequence shares 100% identity with SEQ ID NO: 7 and 10 ; 99.2% with SEQ ID NO: 9 and 93.55% with SEQ ID NO: 11 *
FASTA Accession No. AOP64131; Jan 2014Sequence shares 90.56% identity with SEQ ID NO: 12 and 92.22% identity with SEQ ID NO: 18 *
FASTA Accession No. BAN87027; May 2014Sequence shares 100% identity with SEQ ID NO: 5 *
FASTA Accession No. BAN88347; May 2014Sequence shares 100% identity with SEQ ID NO: 5 *
FASTA Accession No. WP_147509816 1987 Sequence shares 95.12% identity with SEQ ID NO: 4 *
FASTA Accession No. WP_147529944; 1987Sequence shares 91.86% identity with SEQ ID NO: 4 *
FASTA Accession No. WP_151956123; 1987Sequence shares 92.86% identity with SEQ ID NO: 17 *
WEAVER and MATTHEWS "Structure of Bacteriophage T4 Lysozyme Refined at l.7 Å Resolution"; J of Mol Bio (1987), Vol: 193, pages: 189-199 *

Also Published As

Publication number Publication date
NZ728429A (en) 2024-07-05
JP6818349B2 (ja) 2021-01-20
RU2017102306A (ru) 2018-07-26
RU2725809C2 (ru) 2020-07-06
CA2953446A1 (en) 2015-12-30
BR112016030580B1 (pt) 2023-12-19
CN106659748A (zh) 2017-05-10
BR112016030580A2 (pt) 2018-06-19
WO2015200783A2 (en) 2015-12-30
EP3164146A2 (en) 2017-05-10
US20190345467A1 (en) 2019-11-14
EP3164146B1 (en) 2019-12-25
AU2015279705A1 (en) 2017-01-19
WO2015200783A3 (en) 2016-03-03
KR102441211B1 (ko) 2022-09-07
KR20170026505A (ko) 2017-03-08
ES2767294T3 (es) 2020-06-17
GB201701187D0 (en) 2017-03-08
RU2017102306A3 (enExample) 2019-02-26
US10590403B2 (en) 2020-03-17
CN106659748B (zh) 2021-08-31
US20170130214A1 (en) 2017-05-11
US11180744B2 (en) 2021-11-23
GB2543453A (en) 2017-04-19
JP2017526627A (ja) 2017-09-14
EP3164146A4 (en) 2018-03-21
IL249636A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
US11180744B2 (en) Acinetobacter lysins
AU2019222918B2 (en) Antimicrobial peptides and methods of use thereof
JP7386905B2 (ja) Ｒｏｍｏ１由来抗菌ペプチドおよびその変異体
JP7584162B2 (ja) 新規なポリペプチド、融合ポリペプチド、およびこれを含むグラム陰性菌に対する抗生物質
CN112543595A (zh) 抗微生物组合物，其制备方法和用途
JP5140579B2 (ja) 病原菌に対する生体防御を増強するヒアルロン酸結合性ペプチド
TWI403330B (zh) 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
WO2013180011A1 (ja) 抗菌ペプチド及びその利用
WO2004020635A1 (ja) バクテリオファージおよび細菌感染症治療剤
US10220112B2 (en) Cyclic antimicrobial pseudopeptides and uses thereof
WO2013050590A1 (en) Spra1 antimicrobial peptides and uses thereof
HK1237648B (en) Acinetobacter lysins
HK1237648A1 (en) Acinetobacter lysins
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
CN106995485A (zh) 一种分离的内源性抗菌多肽及其应用
WO2025248096A1 (en) Antimicrobial peptides having liquid-liquid phase separation activities

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired